Article Sidebar

Submitted
September 20, 2021
Accepted
September 3, 2023
Published
May 31, 2026
Download
Statistic
Read Counter : 5

Downloads

Download data is not yet available.

Main Article Content

Abstract

Background: Diabetes mellitus (DM) is a metabolic disorder characterized by increased blood sugar levels (> 200 mg/dL). It occurs due to impaired insulin secretion, decreased insulin sensitivity, or a combination of both factors. DM is a chronic degenerative disease that necessitates long-term treatment and can significantly impact kidney function, particularly in patients with diabetic nephropathy.
Objective: This study aims to examine the profile of antidiabetic medications, glycemic control, and the correlation between the pattern of antidiabetic use and glycemic control.
Methods: This study employed a cross-sectional design with retrospective data derived from medical records.
Results: Among the 104 patients who met the inclusion criteria, the most predominant age group was over 44 years (94.2%), with a slight female predominance (51%). A majority of the patients exhibited normal nutritional status, with a body mass index (BMI) ranging from 18.5 to 24.9 (52.9%). The most common complications were macrovascular, including hypertension, stroke, coronary heart disease, diabetic ketoacidosis, dyslipidemia, and gangrene, affecting 75% of the patients.
Conclusion: Statistical analysis using the chi-square test revealed no significant relationship between the pattern of antidiabetic and the glycemic control (p-value = 0.558). This finding suggests that the use of Glycuidone alone, as well as the combination of insulin glargine and aspart, demonstrates good efficacy in achieving glycemic control.

Keywords

Antidiabetic diabetic nephropathy glycemic control

Article Details

License

Copyright (c) 2026 Jurnal Ilmiah Farmasi

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Authors who publish in the Jurnal Ilmiah Farmasi agree to the following terms:

  1. Authors retain copyright and grant Jurnal Ilmiah Farmasi right of first publication with the work simultaneously licensed under a Creative Commons Attribution Licence that allows others to adapt (remix, transform, and build) upon the work non-commercially with an acknowledgement of the work's authorship and initial publication in Jurnal Ilmiah Farmasi.
  2. Authors are permitted to share (copy and redistribute) the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Jurnal Ilmiah Farmasi.
Author Biographies

Emy Oktaviani, Department of Pharmacology and Clinical Pharmacy, Pharmacy Study Program, Faculty of Mathematics and Natural Science, University of Pakuan, Bogor, Indonesia

Farmasi, Fakultas MIPA

Lusi Indriani, Department of Pharmacy, Faculty of Mathematics and Natural Science and Medical, University of Muhammadiyah Riau, Pekanbaru, Indonesia

Farmasi, Fakultas MIPA

Siti Kholilah , Department of Pharmacology and Clinical Pharmacy, Pharmacy Study Program, Faculty of Mathematics and Natural Science, University of Pakuan, Bogor, Indonesia

Farmasi, Fakultas MIPA

Crossref
Scopus
Google Scholar
Europe PMC

References

  1. Akhmad Rizki Fajar. (2017). Analisis Penggunaan Obat Antidiabetik Pada Penderita Diabetes Mellitus Tipe 2 Dengan Hipertensi Di Instalasi Rawat Inap RSUD Dr. Soediran Mangun Sumarso Wonogiri Periode 2017. Skripsi, Fakultas Farmasi Universitas Setia Budi, Surakarta.
  2. Andriane, Y., Sastramihardja, H. S., & Ruslami, R. (2016). Determinan Peresepan Polifarmasi pada Resep Rawat Jalan di Rumah Sakit Rujukan. Global Medical & Health Communication (GMHC), 4(1), 66.
  3. Arimbi, D. S. D., & Indra, R. L. (2020). Pengaruh Pendidikan Kesehatan Terhadap Motivasi Mengontrol Kadar Gula Darah Pada Pasien DM Tipe II. Jurnal Keperawatan Abdurrab, 4(1), 2579-8723
  4. Astuti, A. (2019). Usia, Obesitas dan Aktifitas Fisik Beresiko Terhadap Prediabetes. Jurnal Endurance, 4(2), 319.
  5. Dacroli, E. (2019). Diabetes Mellitus Tipe 2: Alexander Kam Edisi 4. Padang: Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas.
  6. Falah, E. R. (2016). Evaluasi Ketepatan Obat Antidiabetik Dan Antihipertensi Pada Pasien Diabetes Mellitus Tipe 2 Dengan Komplikasi Nefropatidi RSUD“X” Surakarta Januari-Juli 2014. Skripsi, Fakultas Farmasi Universitas Muhammadiyah Surakarta, Surakarta.
  7. Gamayanti, V., Ratnasari, N. L. M. N., & Bhargah, A. (2018). Pola Penggunaan Insulin Pada Pasien Diabetes Mellitus Tipe 2 Di Poli Penyakit Dalam RSU Negara Periode Juli – Agustus 2018. Intisari Sains Medis, 9(3), 68–73.
  8. Hauri, L. Z., & Faridah, I. N. (2019). Penggunaan Obat Pada Pasien Diabetes Melitus Tipe 2 Di 3 Puskesmas Kota Yogyakarta. Tesis, Fakultas Farmasi Universitas Ahmad Dahlan, Yogyakarta.
  9. Inayah, Hamidy, Yulis, M., Yuki, & Rachma, R. P. (2017). Pola Penggunaan Insulin Pada Pasien Diabetes Melitus Tipe 2 Rawat Inap Di Rumah Sakit X Pekanbaru Tahun 2014. Jurnal Ilmu Kedokteran, 10(1), 38.
  10. Ke, J., Li, M., Xu, S., Zhang, W., & Jiang, Y. (2020). Gliquidone Decreases Urinary Protein By Promoting Tubular Reabsorption In Diabetic Goto-Kakizaki Rats. Journal of Endocrinology, 220, 129–141.
  11. Listiani, P. A. R. (2020). Potensi Interaksi Obat Antidiabetik Pada Pasien Diabetes Mellitus Tipe 2. Acta Holist. Pharm, 8 (3), 100 – 104.
  12. Maindoka, F. S., Mpila, D., & Citraningtyas, G. (2017). Kajian Interaksi Obat Pada Pasien Geriatri Rawat Inap Di RSUP Prof. Dr. R. D. Kandou Manado. PHARMACON Jurnal Ilmiah Farmasi-UNSRAT, 6(3), 2302 - 2493.
  13. Nasution, Z. (2013). Nefropati Diabetik Pada Pasien Diabetes Melitus Tipe 2 Yang Terkontrol dan Tidak Terkontrol: Kajian Terhadap Mikroalbumin Urin Sebagai Marker Nefropati Diabetes. Tesis, Fakultas Farmasi Universitas Sumatera Utara, Medan.
  14. Nazilah, K., Rachmawati, E., & Subagijo, P. B. (2017). Identifikasi Drug Related Problems ( Drps ) Pada Terapi Diabetes Melitus Tipe 2 Di Instalasi Rawat Inap RSD Dr . Soebandi Jember Periode Tahun 2015. e-jurnal pustaka kesehatan, 5(3), 413–419.
  15. PERKENI. (2019). Pengelolaan dan Pencegahan Diabetes Mellitus Tipe 2 Dewasa Di Indonesia. Jakarta: PB. PERKENI.
  16. Rahmawaty, A., & Hidayah, P. H. (2020). Hubungan Drug Realated Problems (DRPs) Kategori Interaksi Obat pada Penggunaan Obat Pasien Diabetes Melitus Tipe 2. Cendekia Journal Of Pharmacy, 4(1), 80–88.
  17. Saibi, Y., Hasan, D., & Shaqila, V. (2018). Potensi Interaksi Obat pada Pasien Diabetes Melitus Tipe 2 di Rumah Sakit X Tangerang Selatan. Jurnal Manajemen dan Pelayanan Kefarmasian, 8(3), 100–104.
  18. Sihotang, R. C., Ramadhani, R., & Tahapary, D. L. (2018). Efikasi dan Keamanan Obat Anti Diabetik Oral pada Pasien Diabetes Melitus Tipe 2 dengan Penyakit Ginjal Kronik. Jurnal Penyakit Dalam Indonesia, 5(3), 150.
  19. Sukarmini, N. N. F. dkk. (2018). Efek Penggunaan Obat Antidiabetik Terhadap Luaran Terapi Pada Pasien Diabetes Melitus Tipe 2 Dengan Komplikasi Ulkus Kaki Diabetik Di RSUP Sanglah Denpasar. Jurnal Ilmiah Medicamento, 5(2), 82–87.
  20. Wati, H., & Rodliah. (2019). Asupan Makanan Dan Kadar Gula Darah Pada Pasien Diabetes Mellitus Tipe II Di RS Jatinegara. Binawan Student Journal , 1, 1.
  21. Widodo, C., Tamtomo, D., & Prabandari, A. N. (2016). Hubungan Aktifitas Fisik, Kepatuhan Mengkonsumsi Obat Anti Diabetik Dengan Kadar Gula Darah Pasien Diabetes Mellitus di Fasyankes Primer Klaten. Jurnal Sistem Kesehatan , 2(2), 63-69.